The role of DAB2IP in androgen receptor activation during prostate cancer progression. - Wikidata - awgldk - TriplyDB

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

http://www.wikidata.org/entity/Q39162930

about

DAB2IP in cancer Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer SRC: marker or actor in prostate cancer aggressiveness Androgen receptor phosphorylation: biological context and functional consequences.Tumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments.DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis The role of epithelial plasticity in prostate cancer dissemination and treatment resistance DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.A Novel Monoclonal Antibody Against Human DAB2IP.Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.Are androgen receptor variants a substitute for the full-length receptor?Ras activation revisited: role of GEF and GAP systems.DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1.Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer.microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells.Cytoplasmic gain-of-function mutant p53 contributes to inflammation-associated cancer.miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP.Epigenetic Regulation in Prostate Cancer Progression.Association of rs3787016 in Long Non-coding RNAs POLR2E and rs2910164 in MiRNA-146a with Prostate Cancer: A Systematic Review and Meta-analysis.

P2860

Q26776456-C2B9D329-CCAA-4E02-A082-CEE8E3B35D26 Q26858922-CF2CBAB3-8478-43CC-99C3-DEDEB6B2E13F Q27012541-24ACB9D8-8AF7-44E7-A963-D7D24A11865C Q30394055-5EC3EA65-487D-41A5-AA95-892130EEE343 Q30822011-DF7CF45C-D4B0-45EB-BA94-C83364B6FF92 Q33586771-8C0CD50C-048A-4F99-B1E9-98687C95F408 Q34505037-4A6162E2-C721-42E1-89F9-60FCA273F16C Q35729485-D34A27A6-5354-4CF5-B089-31CF0C878B14 Q36011799-07282904-C812-4307-A2CD-2F2354B5E5C0 Q36628603-612C90E3-036D-4A9E-9D42-12A609691714 Q36688972-4C522A91-0896-4661-8A47-BC3C4631438C Q37084855-2932F883-5A64-4E3D-A5C9-C182D3FD56F2 Q37327806-8399C5D4-E718-4EB9-8CD3-0708D5A7B1A8 Q37745314-B1D14ABC-9C94-44D0-AA78-8DDC5F3592DF Q38350089-17ECCD28-49F8-42AD-84C6-AFD14E0BFF98 Q38381506-F627AFCA-596F-4BE3-B11C-F50E53998EAE Q38973690-95EB3851-07D3-402B-B685-6F485F65EBFD Q39012136-8672CDEE-B8E0-406B-9577-483A914383CB Q40257658-B348A99B-B4BC-4566-8895-FB57D90C4687 Q42494742-8D12DE67-64D2-41B9-A235-8B1C0D337C12 Q53557971-3DA44C58-8F62-47AA-9DC4-663E44E5FC9F Q54974720-5D471333-649F-4813-9819-FA9D5A84F0B1 Q55220671-5A9CC3F4-9F3E-4E05-9CE6-316DCEF456DF

P2860

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

http://www.wikidata.org/entity/Q39162930

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@en

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@nl

type

label

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@en

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@nl

prefLabel

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@en

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@nl

P1433

Q39162930-38881C10-0827-4B3F-9170-944A325CD351

P1476

Q39162930-4F1CFFB3-641F-41FD-AEFB-5A114071B093

P2093

Q39162930-05E4122D-B97C-406C-9271-F4FC74037736

Q39162930-0EF492F9-6B83-4AB4-A732-A389E7755BEF

Q39162930-2461EF6C-7CEB-4FE3-B7A3-C72442DD8C4F

Q39162930-4510E385-14C1-4DC7-B542-BD096E22816F

Q39162930-69AE1888-3A76-45EA-806E-F46DB8067FDB

Q39162930-733C25F3-547A-4C4E-A01F-84A55FEACF68

Q39162930-7C5376CD-FAB5-4750-BF58-48B512E11F4F

Q39162930-7C7E1A92-D8A6-4E6C-BEF0-5A9434E6E1DD

Q39162930-7F61EB96-21B6-4E76-BF32-FE78809E0142

Q39162930-9961F9B6-C40E-4E44-B9C6-C15C36176BF2

P2860

Q39162930-07FBA004-8E80-4195-BCC1-7167313B6388

Q39162930-1329C23A-F169-4095-9841-E6C3FAB4FF03

Q39162930-14AD7824-0E53-4A0C-B661-8685087C60CE

Q39162930-1F275CFB-D250-4C77-AD6D-D94C53C83BEF

Q39162930-1F2809CC-9B08-4ED1-A15A-E67CE1310C6D

Q39162930-20AD383D-D499-4059-9818-946065A81160

Q39162930-22379E7C-FB36-4BB1-9778-008A91E2F8FB

Q39162930-26BBEBFF-476A-48BA-A020-2F5B0647FF75

Q39162930-2B833F0B-7434-4BE8-9E02-A0086A212DD0

Q39162930-44635DAD-3BF5-4880-A147-4BAE4E9D03E9

P2888

Q39162930-28F68FE6-1104-4557-92BA-D030723925CA

P304

Q39162930-6AA4E90F-B9C9-491C-94ED-F78B788D7A32

P31

Q39162930-29536A42-7C85-4639-AC82-DEDE4C0C9950

P356

Q39162930-737E92F1-5930-4E07-89BF-0394AE9C40F8

P407

Q39162930-7D0FC06B-C546-4B0D-98E2-3F64F6714DAA

P433

Q39162930-7B08BBAB-F18F-4E1F-B04D-93925B3B9268

P478

Q39162930-1586A366-020D-42EA-AF9B-8BDE86793510

P577

Q39162930-C028A1AF-BA14-40C2-86C7-303E053E254D

P5875

Q39162930-AAB7F92C-EE12-4342-8645-552FEC65A764

P6179

Q39162930-BA5DBE42-F536-4B57-B571-551863EA5CBD

P698

Q39162930-1253D2CA-9E2B-43DC-B4DD-711FB9A88FC6

P356

P1433

P1476

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

@en

P2093

C Gore

http://www.w3.org/2001/XMLSchema#string

C-L Hsieh

http://www.w3.org/2001/XMLSchema#string

C-R Yang

http://www.w3.org/2001/XMLSchema#string

D He

http://www.w3.org/2001/XMLSchema#string

D Xie

http://www.w3.org/2001/XMLSchema#string

G Alexandrakis

http://www.w3.org/2001/XMLSchema#string

G Xiao

http://www.w3.org/2001/XMLSchema#string

H-C Wu

http://www.w3.org/2001/XMLSchema#string

J Liu

http://www.w3.org/2001/XMLSchema#string

J-T Hsieh

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis

Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Nuclear receptor coregulators: cellular and molecular biology

The development of androgen-independent prostate cancer

Androgen receptor in prostate cancer

SH2 and SH3 domains as targets for anti-proliferative agents.

P2888

P304

1954-1963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2013.143

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236252769

http://www.w3.org/2001/XMLSchema#string

P6179

1035452052

http://www.w3.org/2001/XMLSchema#string

P698

23604126

http://www.w3.org/2001/XMLSchema#string